Related Experiment Video
Updated: Oct 30, 2025
Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing
Published on: October 15, 2019
New Approaches to Profile the Microbiome for Treatment of Neurodegenerative Disease
David R Elmaleh1,2, Matthew A Downey2, Ljiljana Kundakovic2
1Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Abstract:
Progressive neurodegenerative diseases represent some of the largest growing treatment challenges for public health in modern society. These diseases mainly progress due to aging and are driven by microglial surveillance and activation in response to changes occurring in the aging brain. The lack of efficacious treatment options for Alzheimer's disease (AD), as the focus of this review, and other neurodegenerative disorders has encouraged new approaches to address neuroinflammation for potential treatments. Here we will focus on the increasing evidence that dysbiosis of the gut microbiome is characterized by inflammation that may carry over to the central nervous system and into the brain. Neuroinflammation is the common thread associated with neurodegenerative diseases, but it is yet unknown at what point and how innate immune function turns pathogenic for an individual. This review will address extensive efforts to identify constituents of the gut microbiome and their neuroactive metabolites as a peripheral path to treatment. This approach is still in its infancy in substantive clinical trials and requires thorough human studies to elucidate the metabolic microbiome profile to design appropriate treatment strategies for early stages of neurodegenerative disease. We view that in order to address neurodegenerative mechanisms of the gut, microbiome and metabolite profiles must be determined to pre-screen AD subjects prior to the design of specific, chronic titrations of gut microbiota with low-dose antibiotics. This represents an exciting treatment strategy designed to balance inflammatory microglial involvement in disease progression with an individual's manifestation of AD as influenced by a coercive inflammatory gut.
Insights
Gut microbiome dysbiosis contributes to neuroinflammation in aging brains, impacting Alzheimer's disease (AD) progression. Targeting gut bacteria and metabolites offers a novel therapeutic avenue for AD treatment.
Area of Science:
- Neuroscience
- Microbiology
- Immunology
Background:
- Neurodegenerative diseases, particularly Alzheimer's disease (AD), pose significant public health challenges, often linked to aging-related microglial activation.
- Neuroinflammation is a common hallmark of neurodegenerative disorders, but the precise mechanisms by which innate immune function becomes pathogenic remain unclear.
- Current treatment options for AD and related disorders are limited, necessitating innovative therapeutic strategies.
Purpose of the Study:
- To review the growing evidence linking gut microbiome dysbiosis to neuroinflammation and its potential role in neurodegenerative diseases like AD.
- To explore the identification of gut microbial constituents and their neuroactive metabolites as a peripheral therapeutic target.
- To emphasize the need for further human studies to develop targeted microbiome-based treatments for early-stage AD.
Main Methods:
- Review of existing literature on the gut-brain axis, neuroinflammation, and Alzheimer's disease.
- Analysis of studies investigating the role of gut microbiome composition and metabolites in central nervous system health.
- Discussion of potential therapeutic strategies involving modulation of the gut microbiome.
Main Results:
- Increasing evidence suggests gut microbiome dysbiosis is associated with inflammation that can affect the central nervous system.
- Gut microbial metabolites are being identified as potential peripheral targets for neurodegenerative disease treatment.
- The therapeutic application of microbiome modulation for AD is in early stages, requiring substantial clinical validation.
Conclusions:
- Gut microbiome dysbiosis and associated inflammation represent a critical factor in the pathogenesis of neurodegenerative diseases.
- Characterizing individual microbiome and metabolite profiles is essential for developing personalized therapeutic strategies for AD.
- Targeting the gut microbiome, potentially with low-dose antibiotics, offers a promising approach to manage neuroinflammation and AD progression.
Related Concept Videos
01:29Microorganisms in Medicine and Therapeutics
01:22Alzheimer's Disease: Treatment
01:29Modern Molecular Taxonomy